# Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers

> **NCT01153997** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 24 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Cardiac Surgery Requiring Cardiopulmonary Bypass
- Healthy

## Interventions

- **DRUG:** catridecacog
- **DRUG:** placebo
- **DRUG:** catridecacog
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01153997
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01153997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01153997, "Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01153997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*